biosimilars

Clover Initiates Ph I Study of Enbrel Biosimilar in China
Clover Initiates Ph I Study of Enbrel Biosimilar in China
CP Wire
Clover BioPharmaceuticals
Enbrel
Amgen
biosimilars
SCB-808
China
Flag link:
Pfizer Receives European Approval for Herceptin Biosimilar, Trazimera
Pfizer Receives European Approval for Herceptin Biosimilar, Trazimera
CP Wire
Ttrazimera
Pfizer
biosimilars
Herceptin
Europe
Roche
Flag link:
FDA Plans Hearing on Biosimilar Competition, Development
FDA Plans Hearing on Biosimilar Competition, Development
RAPS.org
FDA
biosimilars
competition
Flag link:
Pfizer gets FDA approval for drug similar to Amgen's Neupogen
Pfizer gets FDA approval for drug similar to Amgen's Neupogen
Marketwatch
Pfizer
FDA
biosimilars
Amgen
Neupogen
Nivestym
Flag link:
FDA’s Gottlieb slams drug makers for stalling release of biosimilars
FDA’s Gottlieb slams drug makers for stalling release of biosimilars
Stat
FDA
Scott Gottlieb
biosimilars
competition
Flag link:
Mylan signs U.S. license deal on Humira with AbbVie
Mylan signs U.S. license deal on Humira with AbbVie
Yahoo/Reuters
AbbVie
Mylan
biosimilars
Humira
Flag link:
Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?
Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?
Fierce Pharma
Amgen
biosimilars
Neulasta
Alexion
M&A
Flag link:
Biogen goes deep into biosimilars, slapping down $700M for a major stake in Samsung Bioepis
Biogen goes deep into biosimilars, slapping down $700M for a major stake in Samsung Bioepis
Endpoints
Biogen
Samsung Bioepis
biosimilars
M&A
Flag link:
Amgen Announces Top-Line Data From Remicade Biosimilar Study
Amgen Announces Top-Line Data From Remicade Biosimilar Study
Yahoo/Zacks.com
Amgen
ABP 710
JNJ
Merck
Remicade
biosimilars
rheumatoid arthritis
Flag link:
FDA pulls back biosimilar draft guide amid industry concern
FDA pulls back biosimilar draft guide amid industry concern
Biopharma Dive
FDA
biosimilars
Flag link:
Novartis touts effectiveness, safety of autoimmune drug copies
Novartis touts effectiveness, safety of autoimmune drug copies
Yahoo/Reuters
Novartis
biosimilars
JNJ
Remicade
Amgen
Enbrel
autoimmune disease
Flag link:
Biosimilars could still pack revenue-busting punch, analyst suggests
Biosimilars could still pack revenue-busting punch, analyst suggests
Biopharma Dive
biosimilars
Flag link:
Humira's Sales Will Decline -- and It's Fantastic News for AbbVie
Humira's Sales Will Decline -- and It's Fantastic News for AbbVie
Motley Fool
Humira
AbbVie
biosimilars
Flag link:
Second Patent Cliff Lies Ahead for Pharma With $251 Billion in Sales at Risk by 2024
Second Patent Cliff Lies Ahead for Pharma With $251 Billion in Sales at Risk by 2024
Center for Biosimilars
biosimilars
patent cliff
generics
Flag link:
Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval
Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval
Fierce Pharma
FDA
Fulphila
Mylan Labs
biosimilars
Amgen
Neulasta
Flag link:
How Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales
How Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales
Investors Business Daily
AbbVie
Novartis
Humira
biosimilars
Europe
CHMP
Flag link:
FDA stalls yet another Herceptin copycat, issuing response letter to Amgen/Allergan
FDA stalls yet another Herceptin copycat, issuing response letter to Amgen/Allergan
Endpoints
Amgen
Allergan
FDA
complete response letter
biosimilars
Herceptin
ABP 980
Flag link:
Pfizer Receives Good News for Trazimera (trastuzumab) Biosimilar
Pfizer Receives Good News for Trazimera (trastuzumab) Biosimilar
CP Wire
Pfizer
CHMP
Europe
EMA
Trazimera
trastuzumab
biosimilars
Herceptin
Flag link:
Celltrion resubmits Rituxan candidate in US, Herceptin version to follow
Celltrion resubmits Rituxan candidate in US, Herceptin version to follow
Biopharma Reporter
Celltrion
Rituxan
biosimilars
FDA
Herceptin
Roche
Biogen
CT-P10
Flag link:
The biosimilars era
The biosimilars era
Pharma Times
biosimilars
Flag link:

Pages